Association between prolonged neutropenia and reduced relapse risk in pediatric AML: A report from the children's oncology group
Related Experiment Video
Updated: Mar 19, 2026
Investigating Protein-protein Interactions in Live Cells Using Bioluminescence Resonance Energy Transfer
Published on: May 26, 2014
Lillian Sung1, Richard Aplenc2, Todd A Alonzo3,4
1The Division of Haematology/Oncology, The Hospital for Sick Children, Toronto, ON, Canada.
Insights
Longer neutropenia duration in children with acute myeloid leukemia (AML) correlates with a reduced relapse risk. Sterile site infections did not impact relapse or survival rates in this study.
Area of Science:
- Pediatric Oncology
- Hematology
- Clinical Trials
Background:
- Acute myeloid leukemia (AML) is a significant health concern in children.
- Understanding factors influencing treatment outcomes is crucial for improving survival rates.
- Neutropenia and infections are common complications during chemotherapy for pediatric AML.
Purpose of the Study:
- To investigate the association between sterile site infections and neutropenia duration with relapse risk and overall survival in pediatric AML patients.
- To analyze data from the AAML0531 clinical trial to identify prognostic indicators.
- To explore potential therapeutic strategies based on observed relationships.
Main Methods:
- Analysis of data from 569 pediatric patients with de novo AML from the AAML0531 trial.
- Focus on non-Down syndrome, favorable, and standard-risk patients completing at least 4 chemotherapy cycles.
- Statistical analysis to determine the impact of sterile site infections and neutropenia duration on relapse and survival.
Main Results:
- The number of sterile site infections did not significantly affect the risk of relapse or overall survival.
- A longer duration of neutropenia was associated with a reduced risk of relapse (HR 0.81 per 20 days, p=0.007).
- This association between longer neutropenia duration and lower relapse risk was observed in both favorable and standard-risk pediatric AML patients.
Conclusions:
- Longer neutropenia duration may be a protective factor against relapse in pediatric AML.
- Individualized chemotherapy dosing, potentially guided by pharmacogenomics, could be a valuable strategy to manage toxicity and improve outcomes.
- Further research into the mechanisms underlying neutropenia duration and its effect on AML relapse is warranted.
Abstract:
Objective was to describe the relationship between the number of sterile site infections and duration of neutropenia during the first four cycles of chemotherapy and the risk of recurrence and overall survival in children with newly diagnosed acute myeloid leukemia (AML). AAML0531 was a Children's Oncology Group randomized phase 3 clinical trial that included 1022 children with de novo AML. For this analysis, we focused on non-Down syndrome favorable and standard risk patients who completed at least 4 cycles of chemotherapy without recurrence or withdrawal during protocol therapy. Those receiving hematopoietic stem cell transplantation in first remission were excluded. Five hundred and sixty-nine patients were included; 274 (48.2%) were favorable risk. The median cumulative time with neutropenia between Induction II to completion of Intensification II was 96 (range 54-204) days. Number of sterile site infections did not influence the risk of relapse or overall survival. However, longer duration of neutropenia was associated with a lower risk of relapse (hazard ratio 0.81 per 20 days neutropenia, p = 0.007). Longer duration of neutropenia was associated with a reduced risk of relapse for children with favorable and standard risk AML. Toxicity may be influenced by pharmacogenomics suggesting that individualized chemotherapy dosing may be an effective strategy.
